Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).

Details

Ressource 1Download: 35368047_BIB_35AE3E866FC0.pdf (626.34 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_35AE3E866FC0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
Journal
Leukemia
Author(s)
Maschmeyer G., Bullinger L., Garcia-Vidal C., Herbrecht R., Maertens J., Menna P., Pagano L., Thiebaut-Bertrand A., Calandra T.
ISSN
1476-5551 (Electronic)
ISSN-L
0887-6924
Publication state
Published
Issued date
05/2022
Peer-reviewed
Oui
Volume
36
Number
5
Pages
1215-1226
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The 9th web-based European Conference on Infections in Leukemia (ECIL-9), held September 16-17, 2021, reviewed the risk of infections and febrile neutropenia associated with more recently approved immunotherapeutic agents and molecular targeted drugs for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Novel antibody based treatment approaches (inotuzumab ozogamicin, gemtuzumab ozogamicin, flotetuzumab), isocitrate dehydrogenases inhibitors (ivosidenib, enasidenib, olutasidenib), FLT3 kinase inhibitors (gilteritinib, midostaurin, quizartinib), a hedgehog inhibitor (glasdegib) as well as a BCL2 inhibitor (venetoclax) were reviewed with respect to their mode of action, their immunosuppressive potential, their current approval and the infectious complications and febrile neutropenia reported from clinical studies. Evidence-based recommendations for prevention and management of infectious complications and specific alerts regarding the potential for drug-drug interactions were developed and discussed in a plenary session with the panel of experts until consensus was reached. The set of recommendations was posted on the ECIL website for a month for comments from members of EBMT, EORTC, ICHS and ELN before final approval by the panelists. While a majority of these agents are not associated with a significantly increased risk when used as monotherapy, caution is required with combination therapy such as venetoclax plus hypomethylating agents, gemtuzumab ozogamicin plus cytotoxic drugs or midostaurin added to conventional AML chemotherapy.
Keywords
Antibodies, Monoclonal/adverse effects, Biological Therapy/adverse effects, Febrile Neutropenia/chemically induced, Humans, Immunocompromised Host, Infections/chemically induced, Leukemia, Myeloid, Acute/complications, Leukemia, Myeloid, Acute/drug therapy, Practice Guidelines as Topic, Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
Pubmed
Web of science
Open Access
Yes
Create date
11/04/2022 7:46
Last modification date
23/01/2024 7:23
Usage data